To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published in Annals of Internal Medicine indicated.“We have developed a tool that can ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

If you’ve recently been diagnosed with prostate cancer, or if you’ve had a prostate biopsy to test for prostate cancer, you might have seen the term “Gleason score” or “Gleason grade” on the pathology ...

Driven by the rising global cancer burden, aging populations, and rapid adoption of AI-powered digital pathology, the ...